New JAK Inhibitor for Atopic Dermatitis

Viewing 0 reply threads
  • Author
    • #49017


      On January 14, 2022, the US FDA approved CIBINQO(R) (abrocitinib) oral tablets for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. CIBINQO, which is a Janus kinase (JAK) inhibitor, was approved based on results from 5 clinical trials demonstrating improvement in itching compared with placebo. CIBINQO carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.

      Prescribing information can be found at

Viewing 0 reply threads

You must be logged in to reply to this topic.

New JAK Inhibitor for Atopic Dermatitis
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more